- Home
- DAWN vs FINS Comparison
DAWN vs FINS Comparison
Compare DAWN & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DAWN | FINS |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.8M | 429.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DAWN | FINS |
|---|---|---|
| Price | $9.43 | $13.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $26.56 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 78.0K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.97% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,672,000.00 | N/A |
| Revenue This Year | $15.51 | N/A |
| Revenue Next Year | $49.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.11 | N/A |
| 52 Week Low | $5.64 | $11.61 |
| 52 Week High | $13.53 | $12.57 |
Technical Indicators
Market Signals| Indicator | DAWN | FINS |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 41.50 |
| Support Level | $8.13 | $12.99 |
| Resistance Level | $10.47 | $13.17 |
| Average True Range (ATR) | 0.62 | 0.14 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 53.50 | 15.28 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.